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Abstract
 
Activation of naive CD8 T cells to undergo clonal expansion and develop effector function re-
quires three signals: (a) Ag, (b) costimulation, and (c) IL-12 or adjuvant. The requirement for
the third signal to stimulate Ag-dependent proliferation is variable, making the greatest contri-
bution when Ag levels are low. At high Ag levels, extensive proliferation can occur in vitro or
in vivo in the absence of a third signal. However, despite having undergone the same number
of divisions, cells that expand in the absence of a third signal fail to develop cytolytic effector
function. Thus, proliferation and development of cytolytic function can be fully uncoupled.
Furthermore, these cells are rendered functionally tolerant in vivo, in that subsequent restimu-
lation with a potent stimulus results in limited clonal expansion, impaired IFN-
 
 
 
 production,
and no cytolytic function. Thus, the presence or absence of the third signal appears to be a crit-
ical variable in determining whether stimulation by Ag results in tolerance versus development
of effector function and establishment of a responsive memory population.
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Introduction
 
In addition to central tolerance resulting from negative se-
lection of immature T cells in the thymus, there are mech-
anisms that provide for the induction of peripheral T cell
tolerance. Numerous studies with a diverse array of experi-
mental models make it clear that peripheral tolerance can
take several forms. “Clonal ignorance” results from a failure
of potentially reactive T cells to become activated, and reg-
ulatory lymphocytes may prevent the activation of T cells
in response to peripheral Ag. In addition, peripheral toler-
ance can be established as a result of clonal deletion and/or
induction of nonresponsiveness (1–10). The use of trans-
genic mice, or T cells derived from TCR transgenic mice,
made it possible to clearly demonstrate that tolerance of
CD8 T cells as a result of challenge with Ag can result in
partial or complete deletion of the Ag-specific cells (5, 7, 8,
11, 12). In most cases, establishment of the tolerant state is
preceded by a vigorous response of the cells to the Ag. The
extent of clonal deletion varies and is seldom complete, and
the remaining Ag-specific T cells are nonresponsive and
 
exhibit functional alterations (8–10, 13–16). It is speculated
frequently that levels of Ag or costimulation influence toler-
ance induction; but in most cases, there is little or no direct
evidence for this. Furthermore, there are few in vitro corre-
lates of tolerance induction in CD8 T cells, making it diffi-
cult to study the mechanistic aspects of the phenomenon.
Over the past several years, the central role of dendritic
cells (DC)
 
*
 
 as the “professional APCs” responsible for acti-
vating T cells has become apparent. Cross-presentation of
exogenous Ag by DC (17) appears to be the primary mode
of presentation to naive CD8 T cells, but can lead to either
full activation and development of effector function, or the
induction of tolerance (18, 19). How cross-presentation
can lead to either activation or tolerance, and the factors
that determine the outcome, are not well-defined. The
subset of DC presenting Ag may influence the outcome
(20, 21), but the activation state of the DC is more likely to
be critical (22, 23).
DC become activated in response to engagement of toll-
like receptors by adjuvants such as bacterial cell wall com-
ponents (24, 25) or by ligation of CD40 by CD40L ex-
pressed on CD4 helper T cells (26). One consequence of
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DC, dendritic cells.T
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activation is increased expression of costimulatory ligands
that can provide signal 2 to T cells recognizing the Ag pre-
sented by DC. In particular, B7 ligands are expressed on
resting DC, but expression is up-regulated severalfold upon
activation (27, 28). This is often viewed as being important
for avoiding the tolerance that can occur when T cells rec-
ognize Ag but do not receive signal 2, thus rendering them
anergic (29). However, there is little direct evidence that
increasing B7 expression levels above the basal resting lev-
els is critical for CD8 T cell activation. In fact, there is
some evidence that it may not always be necessary (30) or
sufficient (31, 32) to prevent tolerance.
Activation of DC also stimulates them to produce a vari-
ety of cytokines, and recent studies suggest that some of
these cytokines may provide an essential third signal that is
required to fully activate T cells and avoid tolerance induc-
tion (30, 32–34). This has been studied most extensively
for CD8 T cells, where IL-12 has been shown to provide
the third signal needed for strong proliferation and devel-
opment of cytolytic function in response to Ag and B7
ligand in vitro (33) and in vivo (30, 34), and to shift the
outcome of in vivo Ag stimulation from tolerance to full
activation (30, 32, 34) and establishment of a long-lived
memory population (34). Consistent with this, the CD8
 
 
 
 
 
DC subset most effective for priming CD8 T cells (35, 36)
produces high amounts of IL-12 in response to stimulation,
whereas CD8
 
 
 
 
 
 DC produce little (37).
Development of expanded Ag-specific CD8 T cell pop-
ulations that lack function, and are thus tolerant, has been
observed in a variety of experimental systems (32, 38–42),
but the causes of this have not been defined. We show here
that stimulation of naive CD8 T cells with a high level of
Ag (signal 1) in the presence of costimulation can lead to
strong in vitro proliferation and in vivo clonal expansion,
but the cells fail to develop effector function unless signal 3
in the form of IL-12 is also provided. Furthermore, cells
that initially expand in the absence of signal 3 are rendered
tolerant, in that they fail to develop effector function upon
rechallenge with a stimulus that is normally fully activating
for naive cells. Thus, CD8 T cells can undergo substantial
clonal expansion in response to Ag and costimulation, but
have profoundly different fates depending on whether or
not they receive the third signal.
 
Materials and Methods
 
Mice, Cell Lines, and Reagents. 
 
OT-I mice having a trans-
genic TCR specific for H-2K
 
b
 
 and OVA
 
257–264
 
 were a gift from
Dr. F. Carbone (University of Melbourne, Melbourne, Australia).
OT-I mice were also crossed with Thy1-congenic B6.PL-
Thy1a/Cy (Thy1.1) mice (Jackson ImmunoResearch Laborato-
ries) and bred to homozygosity. The OT-I and OT-I/PL breed-
ing colonies were maintained under specific pathogen-free
conditions at the University of Minnesota. C57BL/6NCr mice
were purchased from the National Cancer Institute. E.G7 tumor cells
(EL-4 thymoma transfected with ovalbumin) were used as targets
in in vitro cytolysis assays, and EL-4 cells were used as controls
for specificity. All directly conjugated fluorescent antibodies were
purchased from BD Biosciences or eBioscience. 25-D1.16 mAb
 
that recognizes the complex of H-2K
 
b
 
 with OVA
 
257–264
 
 (43) was
a gift from Dr. R. Germain (National Institutes of Health, Be-
thesda, MD). Binding of biotinylated 25-D1.16 was detected
with streptavidin-PE (Jackson ImmunoResearch Laboratories).
 
Naive T Cell Purification. 
 
Inguinal, axillary, brachial, cervical,
and mesenteric LN were harvested from OT-I or OT-I/PL mice,
pooled, and disrupted to obtain a single cell suspension, and
passed over Cellect CD8 enrichment columns (Cedarlane Labo-
ratories Limited). Cells were stained with anti–CD44-FITC and
anti–CD8-PE mAbs and sorted using a FACSVantage™ flow cy-
tometer (BD Biosciences). This yielded a population of naive
CD8
 
 
 
 cells that were 
 
 
 
99% CD8
 
 
 
 and 
 
 
 
98% CD44
 
low
 
. Alterna-
tively, OT-I/PL LN cells were enriched for CD8
 
 
 
 CD44
 
low
 
 cells
by negative selection using MACS magnetic cells sorting (Mil-
tenyi Biotec). In brief, cells were coated with FITC-labeled anti-
bodies specific for CD4, B220, I-A
 
b
 
, CD11c, and CD44. Anti-
FITC magnetic MicroBeads (Miltenyi Biotech) were added to
the cells, which were passed over separation columns attached to
the MACS magnet. The cells that did not bind to the column
were collected and were 
 
 
 
95% CD8
 
 
 
 and 
 
 
 
0.5% CD44
 
high
 
.
 
In Vitro Proliferation and Cytotoxicity Assays. 
 
A total of 5 
 
 
 
10
 
4
 
 purified CD8
 
 
 
 T cells and 2 
 
 
 
 10
 
5
 
 Ag-coated latex micro-
spheres were placed in flat-bottom microtiter wells in 200 
 
 
 
l
RPMI 1640 medium supplemented with 10% FCS, 4 mM
 
l
 
-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium
pyruvate, 100 U/ml penicillin and streptomycin, 10 mM HEPES,
and 5 
 
 
 
M 2-ME (RP-10). Where indicated, cultures were sup-
plemented with 2.5 U/ml human rIL-2 (TECIN™; National
Cancer Institute, Biological Resources Branch) and 2 U/ml mu-
rine rIL-12 (Genetics Institute). Proliferation was measured after
2 d by the addition of 1 
 
 
 
Ci [
 
3
 
H]TdR per well for the last 8 h of
culture. Triplicate determinations were done, and SDs are shown.
Alternatively, cell recovery after 3 d of culture was used as the
measure of proliferation, and is expressed as the fold increase in
cells over the input number of cells. Cytolytic activity was deter-
mined in triplicate in a standard 
 
51
 
Cr release assay using E.G7 cells
as targets, with E
 
l
 
-4 cells included as a control for specificity. Re-
sults are expressed as percent-specific release, and error bars show
standard deviations of triplicate values. Effectors and targets were
incubated together for 4 h when effectors were generated in in
vitro cultures; effectors were incubated with targets for 6 h when
effectors were generated by in vivo stimulation of adoptively
transferred OT-I/PL cells. In all figures, the effector to target ra-
tio is expressed as the number of OT-I T cells in the effector
population relative to the number of targets.
 
Antigens and B7-1 on Microspheres.
 
Methods for immobilizing
MHC antigens and costimulatory ligands on 5-
 
 
 
M-diameter la-
tex microspheres have been described previously in detail (44).
Peptide–MHC complexes were a gift from M. Daniels and S.
Jameson (University of Minnesota, Minneapolis, MN). Com-
plexes were prepared using recombinant H-2K
 
b
 
 with the BirA
recognition sequence at the carboxy terminus and human 
 
 
 
2m
that were refolded in the presence of OVA
 
257–264
 
 and biotinylated
(45–47). Avidin was immobilized on 5-
 
 
 
M latex microspheres
using 0.25 
 
 
 
g/10
 
7
 
 beads, and the biotinylated H-2K
 
b
 
–OVA
 
257–264
 
complexes were allowed to bind for 1 h at 4
 
 
 
C. In some experi-
ments, microspheres were coated with DimerX H-2K
 
b
 
:Ig fusion
protein (BD Biosciences) using 2.5 
 
 
 
g DimerX H-2K
 
b
 
:Ig/10
 
7
 
 la-
tex microspheres. Peptide was loaded onto the H-2K
 
b
 
 portion of
the fusion protein by incubating the coated microspheres with
0.1 
 
 
 
M OVA
 
257–264
 
 for 2 h at 37
 
 
 
C, followed by extensive wash-
ing to remove free peptide. When used, B7-1 in the form of a re-
combinant mouse B7-1/Fc chimera (R&D Systems) was coim-T
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mobilized on the microspheres along with Ag using 0.6 
 
 
 
g/10
 
7
 
microspheres (high B7) or 0.15 
 
 
 
g/10
 
7
 
 microspheres (low B7).
For all microsphere preparations, immobilization of proteins was
verified by staining with fluorescent antibodies and analysis with
flow cytometry.
 
Adoptive Transfer and Immunization of OT-I/PL Transgenic
Cells. 
 
Pooled LNs from OT-I/PL mice were disrupted to yield
single cell suspensions and washed with PBS. Before transfer, the
cells were analyzed by flow cytometry to determine the percent-
age of CD8
 
 
 
 cells. Their CD25, CD69, and CD44 phenotypes
were determined to confirm that the cells that were transferred
were not activated. A total of 1.5–3 
 
 
 
 10
 
6
 
 CD8
 
 
 
 cells in 0.3 ml
PBS were transferred via tail vein injection into age- and sex-
matched naive 6–8-wk-old C57BL/6 recipients. Recipient mice
were rested for 24 h before immunization. In some experiments,
OT-I/PL LN cells were labeled with CFSE before transfer to
C57BL/6 mice. LN cells were resuspended to 20 
 
 
 
 10
 
6
 
/ml in
HBSS and warmed in a 37
 
 
 
C water bath for 10 min before add-
ing an equal volume of 6 
 
 
 
M CFSE in HBSS and incubating for
an additional 5 min at 37
 
 
 
C. Cells were washed with ice-cold
RP-10 (to stop the reaction) and washed 2
 
 
 
 with ice-cold PBS
before adoptive transfer. For immunization, the OVA
 
257–264
 
 syn-
thetic peptide (SIINFEKL; Research Genetics) was dissolved in
PBS and injected via the tail vein in a volume of 0.2 ml. Where
indicated, animals received 1 
 
 
 
g of recombinant murine IL-12
(Genetics Institute) or 50 
 
 
 
g LPS in the same injection.
 
Flow Cytometric Analysis of Transferred Cells. 
 
Mice were
killed at the indicated times after adoptive transfer and in vivo
challenge. Spleen cells and LN cells (pooled from axillary, bra-
chial, cervical, inguinal, and mesenteric nodes) were counted by
trypan blue dye exclusion to determine total viable cell counts,
and were stained with the antibodies CD8 and Thy 1.1 to detect
the transferred OT-I/PL cells. Stained cells were analyzed on a
FACSCalibur™ flow cytometer using CELLQuest™ software
(BD Biosciences) to determine the percent and total OT-I/PL
cells in the transferred mice. When OT-I/PL cells were labeled
with CFSE before adoptive transfer, analysis of cell division as in-
dicated by dilution of CFSE fluorescence was done using ModFit
software (BD Biosciences).
 
Intracellular Cytokine Staining After In Vitro Rechallenge.
 
Spleen and LN cells harvested from adoptively transferred mice
were incubated at a concentration of 2 
 
 
 
 10
 
6
 
 cells/ml in RP-10
with 0.2 
 
 
 
M OVA
 
257–264
 
. After 1 h of incubation at 37
 
 
 
C, 0.6
 
 
 
l/ml of the monensin-containing solution GolgiStop (BD Bio-
sciences) was added, and cultures were incubated for an additional
4–5 h at 37
 
 
 
C. Cells were washed and stained with the antibodies
CD8 and Thy 1.1 to mark the OT-I/PL cells. Cells were fixed in
Cytofix buffer (BD Biosciences) for 15 min at 4
 
 
 
C, and perme-
abilized in saponin-containing Perm/Wash buffer (BD Bio-
sciences) for 15 min at 4
 
 
 
C before staining with APC-conjugated
antibody to IFN-
 
 
 
 for 30 min at 4
 
 
 
C. Cells were washed once
with Perm/Wash buffer and once with PBS containing 2% FBS.
Stained cells were analyzed on a FACSCalibur™ flow cytometer
using CELLQuest™ software.
 
In Vivo Killing Assay. 
 
The assay was performed essentially as
described previously by Mueller et al. (48). In brief, a single cell
suspension of C57BL/6 spleen cells was divided into two. One
sample was pulsed with 0.2 
 
 
 
M OVA
 
257–264
 
 for 45 min at 37
 
 
 
C,
washed extensively, and incubated with a high concentration of
CFSE (final concentration of 5 
 
 
 
M). The other population was
incubated without peptide for 45 min at 37
 
 
 
C, washed, and la-
beled with a low concentration of CFSE (final concentration of
0.5 
 
 
 
M). Cells were resuspended at 10
 
8
 
/ml and equal volumes of
the peptide-pulsed, CFSE
 
high
 
 cells and unpulsed, CFSE
 
low
 
 cells
were mixed together, and a total of 2 
 
 
 
 10
 
7
 
 CFSE-labeled spleen
cells were transferred by tail vein injection into mice previously
injected with OT-I/PL cells and immunized as indicated. After
3 h, mice were killed and spleen cells were analyzed by flow cy-
tometry to detect the CFSE-labeled target cells. The two target
populations were distinguished by their different CFSE fluores-
cence intensities. The percent-specific lysis was determined by
the following formula: Ratio 
 
 
 
 (percentage CFSE
 
low
 
/percentage
CFSE
 
high
 
); Percent-specific lysis 
 
 
 
 [1 
 
  
 
(ratio unprimed/ratio
primed) 
 
 
 
 100]. The spleen cells from the in vivo killing assays
were also stained with antibodies to CD8 and Thy 1.1 to deter-
mine the number of OT-I/PL cells in each animal.
 
Results
 
In Vitro Activation with High Signal 1 and Signal 2 Stimu-
lates Proliferation but Not Lytic Function.
 
Artificial APCs in
the form of microspheres having Ag and other ligands on
the surface provide a means of defining the minimal re-
quirements for activating T cells. We had shown previously
that stimulation of naive CD8 T cells with native class I Ag
on microspheres at physiological densities required addition
of both IL-2 and IL-12 for proliferation and development
of cytotoxic function to occur (33). When the B7-1 ligand
was included on the microspheres to provide costimula-
tion, the responses still depended on the addition of IL-12.
We have now found that the requirement for a third signal
for proliferation can be overcome when TCR engagement
is very high (i.e., at high levels of signal 1), but that devel-
opment of effector function remains dependent on the
third signal. This was first observed in experiments using
immobilized anti-TCR mAb to provide signal 1 (unpub-
lished data), but can also be seen when very high Ag sur-
face densities are achieved by using immobilized recombi-
nant H-2K
 
b
 
 that has been refolded in the presence of
OVA
 
257–264
 
 peptide so that the majority of the class I pro-
teins have the relevant peptide Ag bound.
When microspheres were coated at a low density, using
the refolded complex at 0.001 
 
 
 
g/10
 
6
 
 beads, and used to
stimulate naive OT-I CD8 T cells specific for the complex
(49), proliferation (Fig. 1 A) and killing (Fig. 1 B) only oc-
curred if both IL-2 and IL-12 were added. This low density
is similar to the density of the Ag complex present on
OVA-transfected E.G7 cells, based on staining with the 25-
D1.6 mAb (43) that recognizes the Kb–OVA
 
257–264
 
 com-
plex (unpublished data). When a 100-fold higher density of
Ag complex was used, naive OT-I cells proliferated vigor-
ously when just IL-2 was added, and proliferation was not
further increased upon addition of IL-12 (Fig. 1 A). How-
ever, despite this vigorous proliferative response in the ab-
sence of IL-12, the cells failed to develop lytic effector
function unless IL-12 was added (Fig. 1 C). This was the
case at all times examined; stimulation with Ag and IL-12
results in no lytic activity at 24 h, weak activity at 48 h,
maximal activity at 72 h, and declining activity at 96 h (un-
published data), whereas cells resulting from stimulation
with just Ag and IL-2 have no cytolytic activity at any of
these times (unpublished data). Thus, at high levels of TCRT
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engagement, optimal proliferation requires only IL-2, but
development of cytolytic function requires IL-12 addition-
ally; whereas at low TCR engagement levels, both cyto-
kines are required for proliferation as well as differentiation.
TCR engagement by Ag on APCs is normally accompa-
nied by costimulation provided by B7 ligands on the APCs.
To determine whether CD28 engagement might circum-
vent the requirement for IL-12 in induction of cytolysis,
microspheres having K
 
b
 
–OVA
 
257–264
 
 complex coimmobi-
lized with B7-1 were prepared (50) and used to stimulate
naive OT-I T cells. Effective costimulation was apparent in
that proliferation and clonal expansion occurred without
addition of exogenous IL-2 when B7-1 was included on
the microspheres (Fig. 2 A). Nevertheless, development of
cytolytic function only occurred when IL-12 was available,
regardless of the amount of IL-2 added (Fig. 2 B). Thus,
development of cytolytic function remains dependent on
the third signal provided by IL-12 even when signal 2 is
provided by CD28 binding to B7-1.
 
In Vivo Activation with High Ag Dose Stimulates Prolifera-
tion but Not Lytic Effector Function.
 
There are a number of
works describing CD8 T cell populations that have ex-
panded in vivo but lack effector function (32, 38–42). To
determine if a high level of signal 1 might stimulate in vivo
clonal expansion without leading to development of effec-
tor function, experiments were done using adoptive trans-
fer of OT-I T cells into normal C57BL/6 recipients to al-
low quantitation of the Ag-specific T cell response in a
 
relatively normal immune system (51). OT-I cells were
adoptively transferred by intravenous (tail vein) injection
and allowed to equilibrate in the recipient’s immune sys-
tem for 1 d. Mice were challenged with varying doses of
OVA
 
257–264
 
 peptide alone, or along with IL-12. 3 d later, at
the peak of the response (34), the numbers of OT-I cells in
the LN and spleen were determined and cytotoxicity was
measured for the populations. At low peptide concentra-
tions, clonal expansion was minimal in the absence of IL-
12, but was at maximal levels when IL-12 was coadminis-
tered (Fig. 3 A). Clonal expansion in response to peptide in
the absence of IL-12 increased in a dose-dependent man-
ner, whereas increasing the peptide dose above 2 
 
 
 
g in the
presence of IL-12 did not increase the number of OT-I T
cells. Very similar results were obtained when peptide was
administered along with LPS as an adjuvant (Fig. 3 B).
In the same experiment, cytolytic activity of CD8 T cells
from spleens of adoptive transfer recipients challenged with
peptide Ag and IL-12 could be detected directly ex vivo in
a standard 
 
51
 
Cr release assay (Fig. 3 C). In the experiment
shown in Fig. 3 C, the effector/target ratio is expressed as
the number of OT-I cells present in the population. De-
spite large clonal expansion of OT-I cells in response to just
peptide Ag, no cytolytic activity could be measured for
these populations (Fig. 3 C). The cytolytic activities in-
duced in OT-I cells by peptide or peptide and IL-12 were
more directly determined using an in vivo assay of specific
Figure 1. IL-12 is required for
both proliferation and develop-
ment of effector function at low
Ag levels, but only for develop-
ment of effector function at high
Ag levels. Microspheres were
coated with either 0.1 or 0.001
 g Kb/OVA/106 microspheres.
The Kb–OVA complex was pre-
pared by refolding recombinant
heavy chain in the presence of
peptide and  2m, as described in
Materials and Methods. (A)
CD44low CD8  OT-I cells were
stimulated with microspheres in
the presence of the indicated cy-
tokines and proliferation was de-
termined on day 2 by measuring
incorporation of [3H]TdR. (B)
CD44low CD8  OT-I cells were
stimulated with microspheres
made using 0.001  g Kb/OVA
per 106 microspheres in cultures
with the indicated cytokines.
Cells were harvested on day 3 and
a 4-h 51Cr release assay was done
using E.G7 cells as targets. (C) As
described in B, but using 0.1  g
Kb/OVA per 106 microspheres.
Figure 2. Costimulation does not replace a requirement for IL-12 for
the induction of cytolytic function. Microspheres were coated with
DimerX H-2Kb:Ig either alone or along with B7.1-Ig at low or high con-
centrations, and pulsed with OVA257–264 as described in Materials and
Methods. These microspheres were used to stimulate MACS column-
purified CD44low CD8  OT-I cells in the presence of the indicated cyto-
kines. (A) Proliferation was determined by counting the number of viable
cells after 3 d of culture and expressed as the fold increase over input cell
number. (B) Cells were assayed for lytic activity on day 3 using a 4-h 51Cr
release assay using E.G7 cells as targets. Results are expressed as percent-
specific lysis at various effector/target cell ratios.T
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killing. C57BL/6 spleen cells, unpulsed or pulsed with
OVA257–264 peptide, were labeled with different levels of
CFSE fluorescent dye and injected into mice 3 d after chal-
lenge. 3 h later, spleen cells were harvested and flow cy-
tometry was done to determine the numbers of cells having
low (unpulsed) and high (pulsed) levels of CFSE. The ratio
of these two populations in mice not challenged with Ag
defines the 0% lysis level, and the ratios in the challenged
mice can be converted to percent-specific lysis based on
this. Consistent with the results of the ex vivo 51Cr release
assay, minimal specific lysis of peptide-pulsed targets oc-
curred in mice that received just peptide, whereas the ma-
jority of the peptide-pulsed targets were specifically elimi-
nated in the mice that received peptide and IL-12 (Fig. 3
D). In this experiment, the total number of OT-I cells in
the spleens of the unchallenged mice (transfer only) was
0.3   105, 2.4   105 in mice that received just peptide,
and 10.2   105 in the mice challenged with peptide and
IL-12. Thus, as in the in vitro experiments, high signal 1
levels in vivo can stimulate extensive clonal expansion, but
the cells fail to develop lytic effector function.
Although high doses of peptide alone stimulate a large
increase in the number of Ag-specific CD8 T cells, the ex-
tent of clonal expansion in the spleen and LN was not as
great as when IL-12 or LPS adjuvant were administered
(Fig. 3, A and B), at least over the peptide dose range that
was examined. This raised the possibility that cells might
undergo fewer rounds of division when stimulated with
just Ag, and that failure to develop cytotoxic activity might
be related to this. This was examined by labeling OT-I
cells with the fluorescent dye CFSE before adoptive trans-
fer and challenge. As the cells divide in vivo the dye is di-
luted twofold with each division, allowing a determination
of the number of rounds of division that the cells in the
population have undergone.
When CFSE-labeled OT-I cells were adoptively trans-
ferred and the recipients left unchallenged, CFSE levels re-
mained high 3 d later (Fig. 4 A), which is consistent with an
absence of clonal expansion of the cells. In contrast, chal-
lenge with either peptide alone (Fig. 4 B) or peptide and IL-
12 (Fig. 4 C) resulted in extensive dilution of the dye 3 d
later as a result of the clonal expansion that occurs in re-
sponse to Ag. The extent of CFSE dilution was essentially
the same in response to peptide in the presence or absence
of IL-12, indicating that the cells had undergone a compara-
ble number of rounds of division, even though challenge
with peptide alone resulted in somewhat less clonal expan-
sion and no cytolytic function (unpublished data).
This was examined in more detail by comparing the
numbers of OT-I cells present on days 2 and 3 of the re-
sponse, and the average number of divisions that the cells
had undergone. 2 d after challenge, the OT-I cells had ex-
panded comparably to peptide with or without IL-12 (Fig.
4 D). By day 3, there was little further increase in OT-I cell
numbers in the mice that received just peptide, whereas
OT-I cells numbers increased substantially between days 2
and 3 in mice that received peptide and IL-12 (Fig. 4 D).
Despite the difference in numbers of cells, CFSE dye dilu-
tion indicated that cells in both populations had undergone
the same average number of divisions on both days 2 and 3
(Fig. 4 E). Thus, although the OT-I cells in mice that re-
ceived just peptide continued to proliferate between days 2
Figure 3. In vivo activation of CD8  cells with high Ag dose stimu-
lates proliferation but not lytic effector function. (A) C57BL/6 mice re-
ceived OT-I/PL LN cells by adoptive transfer on day  1 and were chal-
lenged on day 0 with the indicated amounts of OVA257–264 peptide either
alone or with 1  g/ mouse of IL-12. Spleens were harvested on day 4,
and the number of OT-I/PL cells was determined by flow cytometry
analysis as described in Materials and Methods. The values shown are av-
erages of duplicate mice and the error bars represent the ranges. (B)
C57BL/6 mice received OT-I/PL LN cells by adoptive transfer on day
 1 and were challenged on day 0 with the indicated amounts of
OVA257–264 peptide either alone or with 50  g/mouse of LPS. Spleens
were harvested on day 3, and the number of OT-I/PL cells was deter-
mined by flow cytometry. The values shown are averages of duplicate
mice and the error bars represent the ranges. (C) Spleen cells from the an-
imals described in A that received 10  g of peptide, with and without
IL-12, were assayed for lytic activity against 51Cr-labeled E.G7 targets at
spleen cell/target ratios of 200, 100, 50, and 25:1. These ratios were con-
verted to OT-I/PL target ratios by multiplying by the percent OT-I/PL
cells in each spleen cell population. The results shown are for one of the
two animals in each treatment group; splenocytes from the other animal
in each group showed essentially identical lytic activity. (D) C57BL/6
mice received OT-I/PL LN cells by adoptive transfer on day  1 and
were left unchallenged (transfer only) or challenged with 10  g
OVA257–264/mouse alone (peptide only) or with 1  g/mouse of IL-12
(peptide   IL-12). On day 3, mice were injected with equal numbers of
unpulsed and OVA257–264-pulsed C57BL/6 spleen cells that were labeled
with low and high concentrations of CFSE, respectively. Spleens were
harvested after 3 h and the cells were analyzed for the preferential loss of
peptide-pulsed, CFSEhigh versus unpulsed, CFSElow target cells. Histo-
grams show the CFSEhigh and CFSElow cells from one of two identically
treated mice; the percent lysis, calculated as described in Materials and
Methods, is indicated.T
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and 3, this was not reflected in an increased number of
cells. These results suggest that IL-12 may provide a sur-
vival advantage to the responding cells to allow continued
clonal expansion between days 2 and 3. The results also
demonstrate that the difference in cytolytic activity be-
tween the two populations (Fig. 3 and unpublished data) is
not due to the cells that expand in response to just peptide
having undergone fewer rounds of division.
Production of IFN-  by CD8 T Cells Stimulated In Vivo in
the Absence and Presence of IL-12. Production of IFN-  is
an important effector function of CD8 T cells. Therefore,
we examined the ability of OT-I cells stimulated by in vivo
administration of peptide in the absence or presence of IL-
12 to perform this function. Mice bearing adoptively trans-
ferred OT-I cells were challenged; 3 d later, cells in the LN
and spleen were examined to determine the number of
OT-I cells present, their cytolytic activity, and their ability
to produce IFN-  upon in vitro restimulation with pep-
tide. IFN-  production was determined by intracellular
staining with an IFN- –specific mAb 5–6 h after in vitro
restimulation with peptide.
A small number of OT-I cells from unchallenged mice
produced IFN-  (Fig. 5 A) consistent with a recent study
demonstrating that naive human CD8 T cells are capable of
rapid IFN-  production in response to Ag (52). Challenge
with peptide alone resulted in about a twofold increase in
the fraction of OT-I cells that produced IFN- , whereas
Figure 4. OT-I/PL cells from mice immunized with peptide alone or
peptide and IL-12 undergo comparable numbers of divisions. C57BL/6
mice received CFSE-labeled OT-I/PL LN cells by adoptive transfer on
day  1 and were left unchallenged or challenged with 2  g OVA257–264/
mouse either alone or with 1  g/mouse of IL-12 on day 0. On days 2
and 3, LN cells were analyzed by flow cytometry to determine the num-
ber of OT-I/PL cells in each animal, and the amount of cell division by
OT-I/PL cells was determined by analyzing CFSE fluorescence using
ModFit software. (A–C) CFSE fluorescence of LN cells from mice im-
munized as indicated, gated on CD8  Thy1.1  populations. The open
histograms are the CFSE profiles, and the shaded histograms represent the
subpopulations of cells that have undergone the same numbers of divi-
sions as determined by deconvolution of the CFSE profiles using ModFit
software. The fluorescence intensity of the endogenous cells was about
twofold lower than that of the CFSE-labeled cells (not depicted), demon-
strating that the OT-I cells being examined have not become CFSE neg-
ative. (D) Comparison of the number of OT-I/PL cells recovered on days
2 and 3. (E) Comparison of the average number of cell divisions, calcu-
lated using ModFit software, on days 2 and 3 after immunization.
Figure 5. CD8  T cells stimulated by peptide in the absence or pres-
ence of IL-12 develop the ability to produce the effector cytokine IFN- .
C57BL/6 mice received OT-I/PL LN cells by adoptive transfer on day
 1 and were left unchallenged or challenged with 10  g OVA257–264/
mouse either alone or with 1  g/mouse of IL-12 on day 0. (A) On day 3,
LN and spleen cells were harvested and incubated in vitro with peptide;
cells were fixed, permeabilized, and stained to detect IFN-  production
as described previously in Materials and Methods. Histograms are gated
on endogenous CD8  (Thy1.1-negative lymphocytes [thin line]) or gated
on transgenic CD8  (Thy1.1-positive lymphocytes [bold line]). The per-
centage of OT-I/PL cells expressing IFN-  is shown. Results shown are
for one of two animals in each group; results were essentially the same for
the other animal in each group. (B) On day 3, LN and spleen cells were
analyzed by flow cytometry to determine the number of OT-I/PL cells in
each animal, and the total number of IFN- –producing OT-I/PL cells
was calculated by multiplying the percent IFN-   by the total number of
OT-I/PL cells. Results shown are the average from two animals; error
bars represent the range. (C) On day 3, LN and spleen cells were assayed
for lytic activity against 51Cr-labeled E.G7 targets at LN or spleen cell:tar-
get cell ratios of 100, 50, 25, and 12.5:1. These ratios were converted to
OT-I/PL target ratios by multiplying by the percent OT-I/PL cells in
each LN or spleen cell population. The results shown are for one of the
two animals in each treatment group, the other animal in each group
showed essentially identical lytic activity.T
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challenge with peptide and IL-12 caused a three- to fivefold
increase (Fig. 5 A). As expected, the number of OT-I cells
increased substantially in mice challenged with peptide, and
clonal expansion was greater when the mice also received
IL-12 (Fig. 5 B). The clonal expansion that occurs in re-
sponse to just peptide, together with the increase in the
fraction of cells that can make IFN-  (Fig. 5 A), results in a
substantial increase in the number of Ag-specific T cells ca-
pable of carrying out this function, in comparison to mice
that have not been challenged (Fig. 5 B). Thus, although
Ag in the absence of a third signal does not induce cytolytic
effector function (Fig. 5 C), it does result in a significant in-
crease in the number of Ag-specific cells that appear to be
functionally competent with respect to IFN-  production.
CD8 T Cells That Expand In Vivo in Response to High Sig-
nal 1 without Signal 3 Are Tolerant. CD8 T cells that re-
spond to high levels of Ag alone undergo substantial clonal
expansion but do not develop cytolytic effector function
(Fig. 3). To determine if these cells could be subsequently
restimulated to develop effector function, mice adoptively
transferred with OT-I cells were challenged with either
peptide alone or peptide and IL-12. 28 d later, the mice
were rechallenged with peptide and LPS adjuvant, and the
number and cytolytic activity of OT-I cells in the spleen
was determined 3 d later. OT-I cells were detectable in the
previously primed mice at day 28 without rechallenge, and
expressed high CD44 levels indicating that they had re-
sponded to the initial challenge. Clonal expansion in the
LN and spleen occurred upon rechallenge with peptide and
LPS when the initial challenge was with either peptide
alone or peptide and IL-12, but was greater when IL-12
was present during the primary stimulation (Fig. 6, A and
B). In a total of four experiments, cells present in LN at
 30 d after priming with peptide alone expanded 8.6  
5.8-fold upon rechallenge. In every experiment, greater
expansion occurred for the population resulting from prim-
ing with peptide and IL-12, averaging 58.7   25.6-fold
expansion. Similar results were obtained when OT-I cells
from the spleens were examined. Thus, cells that respond
initially to Ag in the presence of IL-12 have greater capac-
ity to expand upon secondary challenge.
Even greater differences in these populations are seen
with respect to the ability of the cells to acquire functional
activity. Cells in the LN and spleen from mice primed ini-
tially in the presence of Ag and IL-12 developed potent cy-
tolytic activity in the secondary response, whereas those that
had responded initially to peptide only did not (Fig. 6, C
and D). In three additional independent experiments exam-
ining cytolytic activity after initial priming with 10  g of
peptide, all mice (n   8) primed with peptide alone had no
lytic activity, and in one experiment where initial priming
was with 2  g of peptide, the mice (n   4) primed with
peptide alone had no lytic activity. Cells primed with pep-
tide alone also had a reduced capacity to produce the effec-
tor cytokine IFN- ; fewer of the cells produced IFN- 
upon restimulation (Fig. 7, A and B) and those that did,
produced less (Fig. 7, C and D). Thus, cells that make an
initial response to Ag in the absence of a third signal un-
dergo only weak clonal expansion upon strong secondary
stimulation, are defective in IFN-  production, and fail to
develop cytolytic activity; i.e., they are functionally tolerant.
Discussion
The initial suggestion that naive CD8 T cells require a
“third signal” in addition to Ag (signal 1) and costimulation
Figure 6. CD8  T cells that expand in vivo in response
to peptide in the absence of IL-12 are unable to develop
lytic effector function after secondary challenge with pep-
tide and adjuvant. C57BL/6 mice received 3   106 OT-I/
PL LN cells by adoptive transfer on day  1 and were chal-
lenged on day 0 with 10  g OVA257–264 either alone or
with 1  g/mouse of IL-12. After 40 d, mice were left un-
challenged, or were rechallenged with 10  g OVA257–264
with 50  g LPS. (A and B) After an additional 3 d, LN and
spleen cells were analyzed by flow cytometry to determine
the number of OT-I/PL cells in each mouse. Results
shown for mice that did not receive a secondary challenge
are the average of two animals; error bars represent the
range. Results for mice that were rechallenged with pep-
tide and LPS represent the average of four (primary with
peptide) or three (primary with peptide   IL-12) animals;
SDs are shown. (C and D) LN and spleen cells from ani-
mals that were rechallenged with peptide and LPS were
assayed for lytic activity against 51Cr-labeled E.G7 targets at
total viable cell:target ratios of 100, 50, 25, and 12.5:1.
These ratios were converted to OT-I/PL ratios based on
the percentage of OT-I/PL cells in each population. Re-
sults for the individual mice in each group are shown. LN
and spleen cells from mice that did not receive a secondary challenge with peptide and LPS had no lytic activity at this time, whether the primary chal-
lenge was with peptide alone or peptide and IL-12 (not depicted). The results shown are from one of four essentially identical experiments.T
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(signal 2) came from studies using artificial APC, micro-
spheres coated with class I MHC–peptide complexes, and
B7 ligand. Memory CD8 T cells from TCR transgenic
mice proliferated vigorously and developed cytolytic effec-
tor function in response to the artificial APC, whereas na-
ive cells expressing the same TCR failed to respond unless
IL-12 was provided (33). Consistent with these in vitro re-
sults, in vivo studies examining responses of adoptively
transferred TCR transgenic CD8 T cells have shown that
IL-12 could act as a potent adjuvant (34). Administration of
peptide Ag alone resulted in only weak clonal expansion
and failure to develop a memory population. In contrast,
peptide Ag administered with either complete Freund’s ad-
juvant or IL-12 stimulated strong clonal expansion, devel-
opment of lytic effector function, and establishment of a re-
sponsive memory population. IL-12 had this effect even
when the adoptive transfer recipients lacked the IL-12 re-
ceptor, indicating that IL-12 was acting directly on the
transferred CD8 T cells (30).
These initial studies used relatively low levels of Ag; i.e.,
levels in vitro that were similar to those on Ag-expressing
cell lines and levels in vivo that gave optimal responses
when delivered with adjuvant. However, as shown here,
high levels of Ag, as might be reached during a virus infec-
tion, can stimulate strong proliferation in the absence of IL-
12 both in vitro (Figs. 1 and 2) and in vivo (Figs. 3 and 4).
In other work, we have found that IL-12 stimulates higher
and more prolonged expression of CD25 on the cells than
can be achieved with just Ag and B7 costimulation, thus
rendering the cells more responsive to low levels of IL-2
(53). This contribution to the proliferative response be-
comes less important at high signal 1 levels (Figs. 1–4), per-
haps as a result of increased IL-2 production under these
conditions. IL-12 also appears to increase clonal expansion
by enhancing survival of the proliferating cells. At high Ag
levels in vivo, clonal expansion in the absence or presence
of IL-12 is comparable on day 2 as measured by either the
number of cells recovered or the number of divisions the
cells have undergone (Fig. 4, D and E). By day 3, the cells
have divided further, and the average number of divisions
remains the same in the absence or presence of IL-12 (Fig.
4 E). However, by day 3, the number of OT-I T cells re-
covered is markedly less in the absence of IL-12 (Fig. 4 D),
suggesting that survival is impaired. Marrack and colleagues
have shown that adjuvants increase the survival of activated
T cells (54), and increase the expression of Bcl-3 (55), a
member of IkB family that can promote T cell survival.
Thus, although high levels of Ag can stimulate comparable
cell division in the presence or absence of a third signal, it
appears that the extent of clonal expansion remains some-
what limited unless a third signal is available to promote
survival (Figs. 3 and 4).
Although high levels of Ag can largely overcome the
need for a third signal for proliferation of naive CD8 T
cells, development of cytolytic effector function remains
completely dependent on the third signal both in vitro
(Figs. 1 and 2) and in vivo (Fig. 3, C and D). Development
of cytolytic function does not require multiple rounds of
division; CD8 cells that have undergone as few as one or
two divisions can become cytolytic (56). In the experi-
ments shown here, failure to develop cytolytic function in
the absence of signal 3 is clearly not due to the cells having
undergone fewer divisions. Thus, proliferation and cy-
tolytic function are completely uncoupled in the absence of
a third signal.
Although naive CD8 T cells that are stimulated to divide
in the absence of signal 3 fail to develop cytolytic effector
function, some of the cells do acquire the ability to pro-
duce IFN- . A small fraction of naive CD8 T cells rapidly
produce small amounts of IFN-  upon stimulation with Ag
(Fig. 5 A), as has recently been reported for naive human
CD8 T cells (52). After expansion, in response to just pep-
tide, a substantially greater fraction produces IFN-  upon
Ag restimulation, and this is further increased when the
primary stimulation is done in the presence of IL-12 (Fig. 5
A). Thus, unlike cytolytic function, production of IFN-  is
not completely dependent on a third signal. Using tetramer
staining, HIV-specific CD8 cells that are able to produce
cytokines, including IFN- , but that lack cytolytic func-
tion have been characterized in peripheral blood in chronic
HIV infection (38).
The substantial clonal expansion that can occur in the
absence of adjuvant/signal 3, together with the significant
increase in the fraction of cells that can produce IFN- , re-
sults in a large increase in the number of cells that can carry
out this effector function. Thus, CD8 T cells that have re-
sponded to Ag in the absence of a third signal, although
lacking cytolytic effector function, have the potential to
Figure 7. CD8  T cells that expand in vivo in re-
sponse to peptide in the absence of IL-12 have reduced
ability to produce IFN-  after secondary challenge
with peptide and adjuvant. LN and spleen cells from
the mice described in Fig. 6 that were rechallenged
with peptide and LPS were incubated in vitro with
OVA257-264 peptide for 5 h; cells were fixed, permeabi-
lized, and stained to detect IFN-  production as de-
scribed in Materials and Methods. (A and B) The per-
centage of OT-I cells in the LN and spleen that were
producing IFN-  is shown. (C and D) The geometric
mean fluorescence intensity of IFN-  staining in the
IFN-    OT-I cells is shown. Results in A–D are the
averages of four (primary with peptide) and three (pri-
mary with peptide   IL-12) mice; SDs are shown.T
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make some contribution to development of an immune re-
sponse. Whether this is important will likely depend on the
response being studied. These observations raise an impor-
tant caution with respect to studies that examine IFN- 
production by CD8 T cells as a measure of their functional
activation; it cannot be assumed that a responding popula-
tion that is capable of IFN-  production has also developed
cytolytic activity.
CD8 T cells that expand in response to high Ag levels in
the absence of signal 3 persist in low but detectable num-
bers. However, these persisting cells are not responsive to
even a potent stimulation with Ag and adjuvant. Thus,
upon restimulation with peptide and adjuvant, they un-
dergo less clonal expansion and fail to acquire lytic effector
function (Fig. 6). In contrast, cells that were previously
stimulated in the presence of signal 3 undergo strong sec-
ondary expansion and reacquire cytolytic function in re-
sponse to the same secondary stimulus. Thus, it appears that
cells that make an initial response to Ag in the absence of
signal 3 are rendered permanently tolerant.
Expanded Ag-specific CD8 T cell populations that lack
function, and are thus tolerant, have been described previ-
ously in a number of experimental systems (32, 38–42), but
in most cases the basis for the acquisition of this phenotype
has not been defined. We would suggest that in many in-
stances this results from cross-presentation of Ag to naive
CD8 T cells in a noninflammatory environment so that
they proliferate in response to signals 1 and 2, but fail to re-
ceive the third signal needed to develop function and avoid
tolerance. In fact, Sherman and colleagues have recently re-
ported results (32, 57) that complement our previous re-
sults (30, 33, 34) and the findings discussed here. Their
studies examined the responses of Clone 4 CD8 T cells
with a transgenic TCR specific for hemagglutinin upon
adoptive transfer into mice that express hemagglutinin in
the   cells of the pancreatic islets. In this model, Ag is
cross-presented by APC in the LN draining the pancreas,
and the Clone 4 cells respond by proliferating at this site,
but fail to develop effector functions. Treatment of the
mice with anti-CD40 mAb to activate DC resulted in en-
hanced proliferation of the Clone 4 cells, as well as an in-
crease in the levels of B7.1 and B7.2 on DC in the draining
LN. However, despite extensive proliferation, the Clone 4
cells still failed to develop cytolytic activity or produce
IFN- . When mice were treated with both anti-CD40
mAb and IL-12, the Clone 4 cells developed both effector
functions. Thus, their results also support a model in which
three signals are required to support clonal expansion and
development of effector function, and avoidance of toler-
ance. Our results differ somewhat from theirs because we
find that a substantial fraction of the cells proliferating in
the absence of signal 3 are able to make IFN-  upon re-
stimulation (Fig. 5).
The evidence available thus far strongly supports a
model in which productive activation of CD8 T cells lead-
ing to cytolytic effector function, and avoidance of toler-
ance, requires that three distinct signals be delivered to the
T cell, and that increasing the level of any one of them
cannot bypass the need for the other two. This is the case
when artificial APC are used in vitro to stimulate the cells
(33), and appears to be the case in vivo as well. As de-
scribed here, even very high levels of Ag fail to support
development of lytic effector function, even though the
cells proliferate (Fig. 3). Similarly, high levels of B7 also
fail to overcome the requirement for the third signal (Fig.
2). This also appears to be the case in vivo because Sher-
man and colleagues, in the experiments described previ-
ously, showed that treatment of mice with anti-CD40
mAb increased levels of B7.1 and B7.2 on DC in the
draining LN, but Clone 4 cells still failed to respond unless
IL-12 was provided (32). Albert et al. (31) also concluded
that a third signal was needed for human CD8 T cells acti-
vation when stimulated by DC cross-presentation of Ag in
an in vitro system. When mature DC expressing high lev-
els of B7.1 and B7.2 were used, the CD8 T cells failed to
develop cytolytic function and were tolerized, but the ad-
dition of IL-12 or IL-1  to the cultures resulted in devel-
opment of effector function. Relatively high concentra-
tions of the cytokines were required, leading the authors
to suggest that some alternative, undefined mechanism al-
lows DC to activate the CD8 T cells. However, it would
seem very likely that IL-12 and other cytokines produced
by DC that are presenting Ag may reach high local con-
centrations at the surface of the bound T cell. Although
IL-12 can clearly provide the third signal, it is not the only
thing that can, because peptide Ag and adjuvant elicit
strong, productive responses by CD8 T cells adoptively
transferred into IL-12–deficient mice (34). In vitro experi-
ments have implicated another soluble factor, in addition
to IL-12, that is produced by splenic APCs and can pro-
vide the third signal, and we are working to identify this
(unpublished data). We have tested a variety of cytokines
in vitro that have failed to support development of cy-
tolytic effector function, including IL-1, 2, 4, 7, 10, 15,
and 18, and IFN- .
Thus, Ag and costimulation-dependent expansion of
CD8 T cells that occurs in the absence of an inflammatory
response appears to lead to the induction of functional tol-
erance of the cells, rather than development of effector
function and a responsive memory population. This sug-
gests the possibility that whether cross-presentation of Ag
by CD8   DC will lead to full activation or tolerance (18,
19, 58) will depend on whether the DC have been acti-
vated to produce IL-12 and/or an alternate signal 3. The
findings discussed here have important implications for
vaccine development, and potentially for understanding
many situations where CD8 T cells have clearly made a re-
sponse to Ag but have failed to control the virus or tumor
growth.
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